(Enriched hematopoetic stem cell infusion(University of Louisville))

概要

基本信息

药物类型

干细胞疗法

别名-

靶点-

作用机制-

治疗领域

免疫系统疾病神经系统疾病遗传病与畸形+ [3]

在研适应症-

非在研适应症

肾上腺脑白质营养不良α-甘露糖苷贮积症α地中海贫血+ [14]

原研机构

University of Louisville

在研机构-

非在研机构

University of Louisville

Talaris Therapeutics, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

8

项与 Enriched hematopoetic stem cell infusion(University of Louisville) 相关的临床试验

NCT02287974 / Terminated临床1/2期IIT

Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs: Study of the Needs of Insulin

To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2 with CLI.

开始日期2011-09-01

申办/合作机构-

NCT01419704 / Withdrawn临床1/2期

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.

开始日期2011-05-01

申办/合作机构

Talaris Therapeutics, Inc.

[+1]

NCT01372228 / Terminated临床1/2期

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

The goal of this research study is to establish chimerism and avoid graft-versus-host-disease (GVHD) in patients with inherited metabolic disorders.

开始日期2011-04-01

申办/合作机构

Talaris Therapeutics, Inc.

[+1]

100 项与 Enriched hematopoetic stem cell infusion(University of Louisville) 相关的临床结果

登录后查看更多信息

100 项与 Enriched hematopoetic stem cell infusion(University of Louisville) 相关的转化医学

登录后查看更多信息

100 项与 Enriched hematopoetic stem cell infusion(University of Louisville) 相关的专利（医药）

登录后查看更多信息

100 项与 Enriched hematopoetic stem cell infusion(University of Louisville) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黏多糖贮积症I型	临床2期	美国	Talaris Therapeutics, Inc.	2011-04-01
黏多醣贮积症II型	临床2期	美国	Talaris Therapeutics, Inc.	2011-04-01
镰状细胞血症	临床2期	美国	Talaris Therapeutics, Inc.	2005-01-01
心脏移植排斥反应	临床2期	-	University of Louisville	-
移植物抗宿主病	临床2期	-	University of Louisville	-
异染性脑白质病变	临床2期	-	University of Louisville	-
异染性脑白质病变	临床2期	-	University of Louisville	-
多发性硬化症	临床2期	-	University of Louisville	-
肾移植排斥反应	临床2期	-	University of Louisville	-
肾移植排斥反应	临床1期	-	University of Louisville	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2023	N/A	多发性骨髓瘤	108	BCMA CAR T therapy	鏇醖憲鏇窪艱窪構壓醖(繭遞構淵蓋齋製鏇構蓋) = 糧窪餘醖襯製窪網顧鏇鹹繭淵壓蓋製獵夢壓鏇 (築繭構選憲蓋構窪鹽夢 ) 更多	-	2023-12-11
				Stem cell infusion	鏇醖憲鏇窪艱窪構壓醖(繭遞構淵蓋齋製鏇構蓋) = 衊鏇齋醖鹽積鑰構選衊鹹繭淵壓蓋製獵夢壓鏇 (築繭構選憲蓋構窪鹽夢 ) 更多
EHA2017	N/A	急性白血病	25	UCBP infusion	淵願夢餘願艱範襯鏇糧(顧鹹艱窪網獵網範顧艱) = No UCBP transfusion-related side effects were found. 醖壓糧襯鑰鏇網艱簾壓 (憲網鏇鏇鑰築鹽膚鑰顧 )	积极	2017-05-18
				umbilical cord blood plasma infusion (Placebo)